Psychopharmacology

New data show post‑TBI inflammation boosts amyloid; blocking soluble TNF with XPro1595 preserves memory and reduces pain, hinting prevention.

Consensus definition clarifies Alzheimer agitation, reviews FDA-approved brexpiprazole and dextromethorphan-bupropion, and spotlights caregiver burden

PMN310 shows strong 6‑month safety in early Alzheimer disease, with zero ARIA‑E and encouraging tau biomarker shifts before 2027 data.

Northwestern researchers identify a reduced CSF protein signal in schizophrenia and show a synthetic version restores brain circuit activity in mice.

After TBI, soluble TNF sparks Alzheimer-like damage; XPro1595 blocks it in mice, preserving memory and reducing pain—hinting prevention.

FDA clears Simtriyo, a first-in-class NDSRI and central nervous system stimulant for ADHD, offering new symptom and executive-function gains.

Placebo and nocebo effects shape psychiatric care—how expectations and framing boost medication benefit and reduce side effects.

Review centanafadine ahead of the upcoming FDA decision on July 24.

How Austedo’s VMAT2 inhibition reshapes tardive dyskinesia care, while real-world data reveal underdiagnosis, low uptake, and new studies ahead.

Experts unpack placebo and nocebo effects in psychiatry, revealing how expectation, framing, and alliance boost outcomes and curb side effects.

Three new Teva posters show Austedo sustains tardive dyskinesia improvement long term, works in real-world care, and education boosts diagnosis and visits.

Meta-analysis ranks add-on atypical antipsychotics for MDD, comparing symptom response and dropout risks to guide smarter next-step treatment.

New review links lithium and Alzheimer disease treatment, fueling calls for biomarker-guided, low-dose clinical trials testing lithium’s multi-target disease-modifying potential.

COMP360 psilocybin shows rapid, durable gains in treatment‑resistant depression, as psychedelics continue to grow.

Explore how dopamine D2 blockade shapes antipsychotic benefits and risks, revealing dosing pitfalls, polypharmacy harms, and why plasma level monitoring improves outcomes.

New primate data show IV tau-silencing gene therapy cuts brain tau up to 75% with liver-sparing safety, clearing path for 2026 trial.

A panel of expert psychiatrists define deprescribing as ongoing medication review, guiding safer, personalized psychopharmacology amid polypharmacy, misdiagnosis, and fragmented care.

Motivational interviewing can help psychiatrists address long-acting injectable hesitancy in schizophrenia, according to Gerald Maguire, MD.

How do you pick an LAI antipsychotic? Molecule first, delivery system second, Jacob Hanaie, PharmD, shared at SoCal Psychiatry.

At the Southern California Psychiatry Conference, Jason Kellogg, MD, shares insights into the evolution of the MDD pipeline, with an eye on rapid-acting novel mechanisms.

Gerald A. Maguire, MD, shares his experience and insights on the importance of trust and empathy.

Explore newly FDA-approved ADHD treatments and late-stage contenders, plus practical guidance on managing sleep disorders with evidence-based behavioral strategies.

Explore rapid TRD breakthroughs: accelerated TMS like SAINT, emerging neuromodulation tools, near-term psychedelic therapies, and why sharper diagnosis improves outcomes.

AI is reshaping psychopharmacology—from TRD prediction to digital phenotyping—while exposing data limits, workflow hurdles, and safety risks in suicide tools.

Consensus guidance clarifies IV ketamine dosing, monitoring, staffing and consent to support safer, evidence-based depression treatment.